HIV prevention has changed significantly with the development of pre-exposure prophylaxis, commonly called PrEP. For many years, daily oral medication was the main biomedical approach for people who wanted protection from HIV before potential exposure. Long-acting injectable medicines have since added another approach that reduces the need for daily pills. The next stage of HIV prevention research involves even longer-acting technologies, including implants designed to release antiretroviral medicines gradually beneath the skin. These technologies could potentially reduce the frequency of medication administration even further.
Pre-exposure prophylaxis is medication used by people who do not have HIV to reduce the chance of acquiring HIV.
PrEP can be delivered through oral medication or injection. Daily oral PrEP has been used for years and has demonstrated very high effectiveness when taken as prescribed.
The central principle is straightforward: an antiretroviral medicine is present in the body before HIV exposure. If exposure occurs, sufficient drug levels can interfere with viral replication and reduce the likelihood that infection becomes established.
PrEP does not treat established HIV infection. HIV testing is required before starting PrEP because using prevention medication alone during an undiagnosed HIV infection can contribute to drug resistance.
Daily medication can be highly effective, but taking a pill every day requires consistent adherence.
Some people may forget doses, have difficulty maintaining a daily routine, experience stigma around keeping medication, or simply prefer a prevention method that requires less frequent attention.
Long-acting prevention attempts to address this challenge by keeping an effective concentration of medicine in the body for an extended period.
An implant could theoretically release an antiretroviral medicine continuously over months or potentially longer. Instead of remembering a pill every day, a person would receive a small device placed beneath the skin and return for removal, replacement, or monitoring according to the technology's schedule.
This approach could make HIV prevention less dependent on daily medication-taking behavior.
An HIV prevention implant would generally involve a small device positioned beneath the skin.
The device would contain an antiretroviral compound and release controlled quantities of the medicine into surrounding tissue and the bloodstream.
The goal would be to maintain drug concentrations within a protective range for a prolonged period.
The technology would need to balance two competing requirements.
If drug release is too slow, concentrations could fall below protective levels. If release is too rapid, the implant could potentially produce unnecessarily high exposure and run out of medication sooner than intended.
A successful implant would therefore require highly predictable drug delivery.
Daily oral PrEP and a future implant would approach HIV prevention in very different ways.
Daily tablets place responsibility for medication-taking on the individual. This allows treatment to be started or stopped relatively easily under appropriate medical supervision.
An implant would shift much of that responsibility toward a healthcare procedure. Once inserted, medication would continue to be released without requiring a daily pill.
The difference could be particularly important for people who find daily adherence difficult.
At the same time, an implant would introduce new considerations. Placement and removal would require a procedure, and problems involving the device could require medical attention.
Daily PrEP has the advantage of decades of clinical experience and established monitoring practices. Implant technologies must undergo extensive research before their long-term safety and effectiveness can be determined.
The idea of replacing daily pills with a long-acting method is not entirely theoretical.
Cabotegravir is an injectable PrEP medicine administered at scheduled intervals. CDC clinical guidance describes injectable cabotegravir as a PrEP method for preventing sexual transmission of HIV, with injections given after an initial dosing sequence and then at regular intervals.
When taken as prescribed, injectable PrEP is highly effective at reducing sexual HIV transmission.
This demonstrates the broader principle behind long-acting prevention: maintaining medication in the body can reduce dependence on daily pill-taking.
An implant would extend that concept by potentially providing an even longer period of drug delivery.
Lenacapavir has also become important in the development of long-acting HIV prevention.
Unlike a traditional daily tablet, long-acting lenacapavir-based prevention is designed around infrequent administration. Its extended duration has generated substantial interest because reducing dosing frequency could make prevention easier to maintain.
However, an injectable medicine and an implant are not the same technology.
An injection places medication into tissue without leaving a physical device under the skin. An implant introduces a drug-containing device that remains in the body for an extended period.
The two approaches therefore involve different considerations involving drug delivery, procedures, monitoring, reversibility, and manufacturing.
One potential advantage is reduced adherence burden.
With daily PrEP, missed doses can reduce medication exposure and therefore reduce protection. CDC guidance emphasizes taking PrEP as prescribed to maintain adequate drug levels.
An implant could largely remove the need for daily medication-taking.
Once the implant is functioning properly, medication delivery would occur automatically.
However, adherence would not disappear completely. Follow-up appointments, implant replacement, monitoring, and HIV testing would still be important.
A person could miss a scheduled replacement appointment, for example, allowing medication concentrations to decline.
Long-acting prevention therefore changes the type of adherence required rather than eliminating adherence altogether.
HIV testing remains essential regardless of the PrEP delivery method.
PrEP is intended for people who do not have HIV. Starting or continuing prevention medication without appropriate testing can create concerns if an HIV infection is already present.
This issue could become particularly important with long-acting technologies.
A daily pill can be discontinued relatively quickly when necessary. A long-acting implant may continue releasing medicine after a problem is identified.
For this reason, implant-based prevention would require carefully designed testing and monitoring procedures.
Drug resistance is one of the most important scientific considerations for long-acting HIV prevention.
If HIV infection occurs while a long-acting medicine is present at concentrations that are too low to fully suppress viral replication, resistant virus could potentially emerge.
The extended persistence of some long-acting medicines makes this issue especially important.
Researchers therefore need to understand how drug concentrations change over time, how quickly they decline after dosing stops, and how long clinically meaningful drug levels remain in the body.
An implant would need a reliable release profile that minimizes periods during which drug concentrations fall into an ineffective range.
Another important question concerns reversibility.
If someone experiences an adverse reaction to a daily tablet, stopping the medication generally allows drug exposure to decline according to the medicine's pharmacology.
With an implant, removal may stop the primary source of medication, but residual drug could remain in tissue or circulation.
The exact duration would depend on the medicine and implant design.
A practical implant would therefore need a clearly defined strategy for discontinuation, replacement, adverse reactions, pregnancy considerations, drug interactions, and changes in HIV risk.
Long duration is one of the most attractive concepts behind implant technology.
A future device might theoretically provide protection for many months or potentially longer. However, duration alone would not determine whether an implant is suitable for widespread prevention.
The device would need to maintain appropriate drug concentrations throughout the entire period.
Longer duration also creates practical questions.
If the device remains effective for a very long period, what happens if HIV risk changes? What happens if pregnancy occurs? What happens if another medication is required? What happens if side effects develop?
The ideal implant would need to combine long duration with manageable reversibility.
Several potential advantages make implants an important research area.
A long-lasting implant could eliminate the need for daily pill-taking.
A person would not need to store or take a daily HIV prevention tablet.
A properly functioning implant could provide a controlled release of medicine rather than relying on repeated daily doses.
The system could reduce adherence problems caused by forgetting medication.
A single procedure could potentially provide protection for an extended period.
Medication would be delivered automatically according to the implant's design.
These potential benefits are promising, but they must be weighed against the challenges associated with an implanted medical device.
Implants also introduce several disadvantages and uncertainties.
Placement would require a minor medical procedure, and removal could require another procedure.
Skin irritation, pain, inflammation, infection, scarring, or other local complications could potentially occur.
An implant could theoretically break, move, release medicine incorrectly, or fail to provide the intended drug exposure.
If adverse effects occur, medication may not disappear immediately after removal.
Long-lasting low drug concentrations could create challenges if HIV infection occurs.
Producing a reliable implant capable of controlled drug release over long periods can be technically demanding.
Regular HIV testing and clinical monitoring would still be necessary.
No HIV prevention medication should be considered a replacement for broader sexual health measures.
PrEP is designed specifically to reduce HIV acquisition. It does not protect against other sexually transmitted infections.
Condoms can reduce the risk of several STIs and can also help prevent pregnancy.
Consequently, even a highly effective HIV prevention implant would form only one component of a broader prevention strategy.
Pregnancy introduces additional considerations for HIV prevention.
Medication safety during conception, pregnancy, and breastfeeding must be evaluated for each specific PrEP medicine.
An implant would require evidence addressing maternal exposure, fetal development, breastfeeding, drug concentrations, and removal or replacement procedures.
These questions are especially important because an implant could continue releasing medication for an extended period without daily decisions about whether to take another dose.
Probably not immediately.
If HIV prevention implants eventually reach routine clinical use, they would more likely become another prevention method rather than automatically eliminating oral PrEP.
Different people have different medical circumstances, risk patterns, preferences, medication histories, and access to healthcare.
Some may prefer a daily tablet because it does not require an implanted device. Others may prefer a long-acting approach because daily adherence is difficult.
A range of prevention methods could therefore coexist.
Daily oral PrEP remains an established HIV prevention method.
CDC guidance states that daily oral PrEP can substantially reduce HIV acquisition when taken as prescribed. It also remains useful for people who prefer tablets or for circumstances in which long-acting prevention is unsuitable.
Oral PrEP also provides a relatively flexible medication format. Treatment can be adjusted under medical supervision based on changing circumstances.
This flexibility would remain an important advantage even if long-duration implants become clinically established.
Potentially, yes.
Medication adherence can be affected by work schedules, travel, privacy concerns, stigma, memory, mental workload, and changing routines.
A long-acting implant could reduce the number of medication-related actions required over time.
However, the person would still need to attend appointments and undergo HIV testing.
Long-acting prevention should therefore be viewed as a different adherence model rather than a method that eliminates healthcare involvement.
Several areas require strong evidence before HIV prevention implants could become routine.
Researchers would need to establish:
Clinical trials would need to compare implant-based prevention with established PrEP methods rather than simply demonstrating that the device releases medication.
The future of PrEP is likely to involve multiple delivery methods.
Daily tablets remain important because they are familiar, flexible, and supported by extensive clinical evidence.
Injectable PrEP reduces dosing frequency and can be useful for people who prefer injections or have difficulty maintaining daily pill adherence.
Future implants could potentially extend the interval between prevention interventions even further.
Other technologies may also emerge, including longer-lasting formulations, improved drug-delivery systems, and prevention methods designed around individual circumstances.
The broader trend is toward reducing the practical burden associated with HIV prevention while maintaining high levels of protection.
It is important to distinguish HIV prevention from HIV treatment.
PrEP is used before HIV acquisition. Antiretroviral treatment is used by people living with HIV to suppress the virus and protect health.
A prevention implant would therefore be intended for people without HIV who have a potential risk of exposure.
It would not replace a complete HIV treatment regimen.
People with a confirmed HIV infection require an appropriate combination of antiretroviral medicines selected according to clinical circumstances and resistance testing when indicated.
PrEP and post-exposure prophylaxis are different.
PrEP is taken before potential exposure. PEP is an emergency prevention strategy used after a possible HIV exposure and needs to be started promptly.
A long-acting prevention implant would not necessarily replace PEP for an exposure that occurs before preventive protection has been established.
Medical evaluation is important after a potential exposure so that HIV testing and appropriate preventive treatment can be considered.
The success of any long-acting HIV prevention technology would depend not only on effectiveness but also on access.
An implant could require specialized equipment, trained healthcare professionals, insertion and removal procedures, follow-up appointments, and regular testing.
Daily tablets may be easier to distribute through existing pharmacy and clinical systems.
Injectable PrEP also requires scheduled clinical visits.
Healthcare systems would therefore need to evaluate the total cost of the technology, including medication, procedures, testing, monitoring, storage, training, and follow-up.
HIV prevention works best when the method fits an individual's circumstances.
Some people may prefer a daily tablet because it provides control over when medication is taken.
Others may prefer an injection because it reduces the frequency of dosing.
An implant could appeal to people who want an even longer interval between prevention appointments.
The eventual role of implants will therefore depend partly on whether clinical evidence shows that the technology is safe, effective, practical, and acceptable to the people who use it.
HIV prevention implants represent an important area of research because they could potentially address one of the longstanding challenges of PrEP: maintaining consistent medication use over time.
However, implants have not yet replaced daily oral PrEP. Established prevention currently includes oral PrEP and long-acting injectable approaches, while implant technology requires further clinical development.